Last $2.32 USD
Change Today -0.007 / -0.30%
Volume 11.3K
BIOL On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 10:19 AM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

biolase inc (BIOL) Snapshot

Open
$2.27
Previous Close
$2.33
Day High
$2.33
Day Low
$2.27
52 Week High
12/30/13 - $3.53
52 Week Low
11/12/13 - $1.47
Market Cap
102.0M
Average Volume 10 Days
96.4K
EPS TTM
$-0.48
Shares Outstanding
43.9M
EX-Date
08/22/05
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOLASE INC (BIOL)

Related News

No related news articles were found.

biolase inc (BIOL) Related Businessweek News

No Related Businessweek News Found

biolase inc (BIOL) Details

BIOLASE, Inc., a biomedical company, develops, manufactures, and markets lasers in dentistry and medicine in the Unites States and internationally. The company offers Waterlase dental laser systems for cutting soft and hard tissue; and diode laser systems, which are used in soft tissue, pain therapy, and cosmetic procedures, such as teeth whitening. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other specialists to perform a range of dental procedures, including cosmetic and complex surgical applications. The company also markets and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners, and in-office, chair-side milling machines and three-dimensional printers, as well as provides precision intuitive diagnosis and treatment planning solutions. In addition, it offers medical systems comprising Diolase 10 Diode Laser for therapeutic applications consisting of temporary pain relief; topical heating for the purpose of temporarily relieving minor muscle and joint pain and stiffness, minor arthritis pain, muscle spasm, minor sprains and strains, and minor muscular back pain; temporarily increasing local blood circulation; and temporarily relaxing muscles. Further, the company manufactures and sells disposable products and accessories for laser systems, as well as markets flexible fibers and hand pieces. BIOLASE, Inc. has a strategic agreement with Valam, Inc. to develop, market, and sell office-based laser systems to otolaryngologists. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.

220 Employees
Last Reported Date: 03/17/14
Founded in 1984

biolase inc (BIOL) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $205.4K
Chief Medical Officer, Member of Audit Commit...
Total Annual Compensation: $131.8K
Vice President of Business Development
Total Annual Compensation: $155.5K
Vice President of Research and Development
Total Annual Compensation: $250.0K
Regional Sales Director
Total Annual Compensation: $148.2K
Compensation as of Fiscal Year 2013.

biolase inc (BIOL) Key Developments

BIOLASE Names Jeffrey M. Nugent as President and Chief Executive Officer

BIOLASE, Inc. announced that Jeffrey M. Nugent has been named President and Chief Executive Officer by the company's Board of Directors, effective immediately. Nugent has served as Acting Chief Executive Officer and a member of the Board of Directors since June 2014. Nugent has a broad background in the medical device, medical laser technology and dental industries. Most recently, in 2010, he was founder, President, and Chief Executive Officer of Precision Dermatology, Inc.

BIOLASE, Inc. Names Alexander K. Arrow as Chief Medical Officer

BIOLASE, Inc. announced that Alexander K. Arrow, M.D. has been named to the newly-created position of Chief Medical Officer, effective immediately. Dr. Arrow had been the company's President and Chief Operating Officer since 2013 and was a member of the board of directors from 2010 to 2014. Prior to coming to BIOLASE, from 2012 to 2013, Dr. Arrow was Chief Medical and Strategic Officer of Circuit Therapeutics Inc. Dr. Arrow will lead the company's clinical development programs, continue to run the Regulatory/Quality Affairs, Clinical Education & Research departments, and work directly with BIOLASE's new Dental Professional Advisory Board. Dr. Arrow will continue to be active in the company's investor relations programs.

Biolase, Inc. Announces Executive Appointments

On August 27, 2014, the board of directors of Biolase, Inc. appointed Paul N. Clark, a director, to the audit committee of the board. In addition, the board appointed Dr. Jonathan T. Lord, a director, as a member and chairman of the compensation committee of the board, and appointed directors Drs. Lord and Frederic H. Moll to the nominating and corporate governance committee of the board.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOL:US $2.32 USD -0.007

BIOL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bacterin International Holdings Inc $4.52 USD +0.24
Cutera Inc $9.92 USD 0.00
Stereotaxis Inc $2.04 USD +0.01
Uroplasty Inc $2.45 USD +0.03
Vision Sciences Inc/DE $0.87 USD 0.00
View Industry Companies
 

Industry Analysis

BIOL

Industry Average

Valuation BIOL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.8x
Price/Book 29.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOLASE INC, please visit www.biolase.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.